<?xml version="1.0" ?>
<!DOCTYPE PubmedArticleSet PUBLIC "-//NLM//DTD PubMedArticle, 1st January 2023//EN" "https://dtd.nlm.nih.gov/ncbi/pubmed/out/pubmed_230101.dtd">
<PubmedArticleSet>
<PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM" IndexingMethod="Curated"><PMID Version="1">36987602</PMID><DateCompleted><Year>2023</Year><Month>03</Month><Day>30</Day></DateCompleted><DateRevised><Year>2023</Year><Month>05</Month><Day>10</Day></DateRevised><Article PubModel="Print"><Journal><ISSN IssnType="Electronic">1462-0332</ISSN><JournalIssue CitedMedium="Internet"><Volume>62</Volume><Issue>Suppl 1</Issue><PubDate><Year>2023</Year><Month>Mar</Month><Day>29</Day></PubDate></JournalIssue><Title>Rheumatology (Oxford, England)</Title><ISOAbbreviation>Rheumatology (Oxford)</ISOAbbreviation></Journal><ArticleTitle>The global epidemiology of SLE: narrowing the knowledge gaps.</ArticleTitle><Pagination><StartPage>i4</StartPage><EndPage>i9</EndPage><MedlinePgn>i4-i9</MedlinePgn></Pagination><ELocationID EIdType="doi" ValidYN="Y">10.1093/rheumatology/keac610</ELocationID><Abstract><AbstractText>SLE is a global health concern that unevenly affects certain ethnic/racial groups. Individuals of Asian, Black, Hispanic and Indigenous ethnicity/race are amongst those who experience increased prevalence, incidence, morbidity and mortality. Population-based surveillance studies from many regions are few and often still in nascent stages. Many of these areas are challenged by restricted access to diagnostics and therapeutics. Without accurately capturing the worldwide burden and distribution of SLE, appropriately dedicating resources to improve global SLE outcomes may be challenging. This review discusses recent SLE epidemiological studies, highlighting the challenges and emerging opportunities in low- and middle-income countries. We suggest means of closing these gaps to better address the global health need in SLE.</AbstractText><CopyrightInformation>&#xa9; The Author(s) 2023. Published by Oxford University Press on behalf of the British Society for Rheumatology.</CopyrightInformation></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Barber</LastName><ForeName>Megan R W</ForeName><Initials>MRW</Initials><Identifier Source="ORCID">0000-0003-1055-1335</Identifier><AffiliationInfo><Affiliation>Division of Rheumatology, Cumming School of Medicine, University of Calgary, Calgary, Alberta, Canada.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Falasinnu</LastName><ForeName>Titilola</ForeName><Initials>T</Initials><AffiliationInfo><Affiliation>Division of Immunology and Rheumatology, Department of Medicine, Stanford School of Medicine, Stanford, CA, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Ramsey-Goldman</LastName><ForeName>Rosalind</ForeName><Initials>R</Initials><AffiliationInfo><Affiliation>Department of Medicine, Division of Rheumatology, Feinberg School of Medicine, Northwestern University, Chicago, IL, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Clarke</LastName><ForeName>Ann E</ForeName><Initials>AE</Initials><AffiliationInfo><Affiliation>Division of Rheumatology, Cumming School of Medicine, University of Calgary, Calgary, Alberta, Canada.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><GrantList CompleteYN="Y"><Grant><GrantID>P30 AR072579</GrantID><Acronym>AR</Acronym><Agency>NIAMS NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>P30 AR072579</GrantID><Acronym>GF</Acronym><Agency>NIH HHS</Agency><Country>United States</Country></Grant></GrantList><PublicationTypeList><PublicationType UI="D016454">Review</PublicationType><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D013485">Research Support, Non-U.S. Gov't</PublicationType><PublicationType UI="D013486">Research Support, U.S. Gov't, Non-P.H.S.</PublicationType><PublicationType UI="D052061">Research Support, N.I.H., Extramural</PublicationType></PublicationTypeList></Article><MedlineJournalInfo><Country>England</Country><MedlineTA>Rheumatology (Oxford)</MedlineTA><NlmUniqueID>100883501</NlmUniqueID><ISSNLinking>1462-0324</ISSNLinking></MedlineJournalInfo><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D005006" MajorTopicYN="Y">Ethnicity</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D006630" MajorTopicYN="N">Hispanic or Latino</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008180" MajorTopicYN="Y">Lupus Erythematosus, Systemic</DescriptorName><QualifierName UI="Q000453" MajorTopicYN="N">epidemiology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D009017" MajorTopicYN="N">Morbidity</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D044469" MajorTopicYN="N">Racial Groups</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D044466" MajorTopicYN="N">Asian People</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D044383" MajorTopicYN="N">Black People</DescriptorName></MeshHeading></MeshHeadingList><KeywordList Owner="NOTNLM"><Keyword MajorTopicYN="N">SLE</Keyword><Keyword MajorTopicYN="N">epidemiology</Keyword><Keyword MajorTopicYN="N">health disparities</Keyword><Keyword MajorTopicYN="N">incidence</Keyword><Keyword MajorTopicYN="N">low- and middle-income countries</Keyword><Keyword MajorTopicYN="N">lupus</Keyword><Keyword MajorTopicYN="N">prevalence</Keyword></KeywordList></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="received"><Year>2022</Year><Month>8</Month><Day>31</Day></PubMedPubDate><PubMedPubDate PubStatus="accepted"><Year>2022</Year><Month>10</Month><Day>18</Day></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2023</Year><Month>3</Month><Day>30</Day><Hour>6</Hour><Minute>11</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2023</Year><Month>3</Month><Day>29</Day><Hour>3</Hour><Minute>3</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2023</Year><Month>3</Month><Day>30</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">36987602</ArticleId><ArticleId IdType="pmc">PMC10050933</ArticleId><ArticleId IdType="doi">10.1093/rheumatology/keac610</ArticleId><ArticleId IdType="pii">7087226</ArticleId></ArticleIdList><ReferenceList><Reference><Citation>Dall'Era M, Cisternas MG, Snipes K. et al. The incidence and prevalence of systemic lupus erythematosus in San Francisco County, California: the California Lupus Surveillance Project. Arthritis Rheumatol 2017;69:1996&#x2013;2005.</Citation><ArticleIdList><ArticleId IdType="pubmed">28891237</ArticleId></ArticleIdList></Reference><Reference><Citation>Izmirly PM, Wan I, Sahl S. et al. The incidence and prevalence of systemic lupus erythematosus in New York County (Manhattan), New York: the Manhattan lupus surveillance program. Arthritis Rheumatol 2017;69:2006&#x2013;17.</Citation><ArticleIdList><ArticleId IdType="pubmed">28891252</ArticleId></ArticleIdList></Reference><Reference><Citation>Izmirly PM, Ferucci ED, Somers EC. et al. Incidence rates of systemic lupus erythematosus in the USA: estimates from a meta-analysis of the Centers for Disease Control and Prevention national lupus registries. Lupus Sci Med 2021;8:e000614.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC8685969</ArticleId><ArticleId IdType="pubmed">34921094</ArticleId></ArticleIdList></Reference><Reference><Citation>Izmirly PM, Parton H, Wang L. et al. Prevalence of systemic lupus erythematosus in the United States: estimates from a meta-analysis of the centers for disease control and prevention national lupus registries. Arthritis Rheumatol 2021;73:991&#x2013;6.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC8169527</ArticleId><ArticleId IdType="pubmed">33474834</ArticleId></ArticleIdList></Reference><Reference><Citation>Barber MRW, Drenkard C, Falasinnu T. et al. Global epidemiology of systemic lupus erythematosus. Nat Rev Rheumatol 2021;17:515&#x2013;32.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC8982275</ArticleId><ArticleId IdType="pubmed">34345022</ArticleId></ArticleIdList></Reference><Reference><Citation>Magro R, Borg AA.. Characterisation of patients with systemic lupus erythematosus in malta: a population based cohort cross-sectional study. Biomed Res Int 2018;2018:2385386.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6186354</ArticleId><ArticleId IdType="pubmed">30364091</ArticleId></ArticleIdList></Reference><Reference><Citation>Anstey NM, Bastian I, Dunckley H, Currie BJ.. Systemic lupus erythematosus in Australian aborigines: high prevalence, morbidity and mortality. Aust N Z J Med 1993;23:646&#x2013;51.</Citation><ArticleIdList><ArticleId IdType="pubmed">8141691</ArticleId></ArticleIdList></Reference><Reference><Citation>Grennan DM, Bossingham D.. Systemic lupus erythematosus (SLE): different prevalences in different populations of Australian aboriginals. Austr New Zeal J Med 1995;25:182&#x2013;3.</Citation><ArticleIdList><ArticleId IdType="pubmed">7605310</ArticleId></ArticleIdList></Reference><Reference><Citation>Kane BS, Niasse M, Ndiaye AA. et al. Systemic Diseases in Dakar (Senegal): spectrum, epidemiological aspect and diagnostic time-limit. Open J Intern Med 2018;08:196&#x2013;206.</Citation></Reference><Reference><Citation>Chiu YM, Lai CH.. Nationwide population-based epidemiologic study of systemic lupus erythematosus in Taiwan. Lupus 2010;19:1250&#x2013;5.</Citation><ArticleIdList><ArticleId IdType="pubmed">20647248</ArticleId></ArticleIdList></Reference><Reference><Citation>Gergianaki I, Fanouriakis A, Repa A. et al. Epidemiology and burden of systemic lupus erythematosus in a Southern European population: data from the community-based lupus registry of Crete, Greece. Ann Rheum Dis 2017;76:1992&#x2013;2000.</Citation><ArticleIdList><ArticleId IdType="pubmed">28780511</ArticleId></ArticleIdList></Reference><Reference><Citation>Ingvarsson RF, Bengtsson AA, Jonsen A.. Variations in the epidemiology of systemic lupus erythematosus in southern Sweden. Lupus 2016;25:772&#x2013;80.</Citation><ArticleIdList><ArticleId IdType="pubmed">26923282</ArticleId></ArticleIdList></Reference><Reference><Citation>Li S, Gong T, Peng Y, Nieman KM, Gilbertson DT.. Prevalence and incidence of systemic lupus erythematosus and associated outcomes in the 2009-2016 US Medicare population. Lupus 2020;29:15&#x2013;26.</Citation><ArticleIdList><ArticleId IdType="pubmed">31726936</ArticleId></ArticleIdList></Reference><Reference><Citation>Duarte-Garc&#xed;a A, Hocaoglu M, Valenzuela-Almada M. et al. Rising incidence and prevalence of systemic lupus erythematosus: a population-based study over four decades. Ann Rheum Dis 2022;doi:10.1136/annrheumdis-2022-222276.</Citation><ArticleIdList><ArticleId IdType="pubmed">35577385</ArticleId></ArticleIdList></Reference><Reference><Citation>Aringer M, Costenbader K, Daikh D. et al. European League Against Rheumatism/American College of Rheumatology classification criteria for systemic lupus erythematosus. Arthritis Rheumatol 2019;71:1400&#x2013;12.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6827566</ArticleId><ArticleId IdType="pubmed">31385462</ArticleId></ArticleIdList></Reference><Reference><Citation>Duarte-Garcia A, Hocaoglu M, Osei-Onomah SA. et al. Population-based incidence and time to classification of systemic lupus erythematosus by three different classification criteria: a Lupus Midwest Network (LUMEN) study. Rheumatology 2022;61:2424&#x2013;31.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC10061051</ArticleId><ArticleId IdType="pubmed">34718442</ArticleId></ArticleIdList></Reference><Reference><Citation>Petri M, Orbai AM, Alarcon GS. et al. Derivation and validation of the Systemic Lupus International Collaborating Clinics classification criteria for systemic lupus erythematosus. Arthritis Rheum 2012;64:2677&#x2013;86.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3409311</ArticleId><ArticleId IdType="pubmed">22553077</ArticleId></ArticleIdList></Reference><Reference><Citation>Hochberg MC. Updating the American College of Rheumatology revised criteria for the classification of systemic lupus erythematosus. Arthritis Rheum 1997;40:1725.</Citation><ArticleIdList><ArticleId IdType="pubmed">9324032</ArticleId></ArticleIdList></Reference><Reference><Citation>Leong PY, Huang JY, Chiou JY, Bai YC, Wei JC.. The prevalence and incidence of systemic lupus erythematosus in Taiwan: a nationwide population-based study. Sci Rep 2021;11:5631.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7952694</ArticleId><ArticleId IdType="pubmed">33707552</ArticleId></ArticleIdList></Reference><Reference><Citation>Bae EH, Lim SY, Han KD. et al. Trend of prevalence and incidence of systemic lupus erythematosus in South Korea 2015 to 2020: a nationwide population-based study. Korean J Intern Med 2020;35:652&#x2013;61.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7214355</ArticleId><ArticleId IdType="pubmed">31212409</ArticleId></ArticleIdList></Reference><Reference><Citation>Al-Adhoubi NK, Al-Balushi F, Al-Salmi I. et al. A multicenter longitudinal study of the prevalence and mortality rate of systemic lupus erythematosus patients in Oman: Oman Lupus Study. Int J Rheum Dis 2021;24:847&#x2013;54.</Citation><ArticleIdList><ArticleId IdType="pubmed">34058079</ArticleId></ArticleIdList></Reference><Reference><Citation>Mendoza-Pinto C, Etchegaray-Morales I, Garcia-Carrasco M. et al. Twenty-year trends in all-cause mortality of patients with systemic lupus erythematosus in Mexico: results from a nationwide health registry. Lupus 2022;31:382&#x2013;91.</Citation><ArticleIdList><ArticleId IdType="pubmed">35188438</ArticleId></ArticleIdList></Reference><Reference><Citation>Guo Q, Liang M, Duan J. et al. Age differences in secular trends in black-white disparities in mortality from systemic lupus erythematosus among women in the United States from 1988 to 2017. Lupus 2021;30:715&#x2013;24.</Citation><ArticleIdList><ArticleId IdType="pubmed">33535903</ArticleId></ArticleIdList></Reference><Reference><Citation>Yen EY, Singh RR.. Brief report: lupus-an unrecognized leading cause of death in young females: a population-based study using Nationwide Death Certificates, 2000-2015. Arthritis Rheumatol 2018;70:1251&#x2013;5.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6105528</ArticleId><ArticleId IdType="pubmed">29671279</ArticleId></ArticleIdList></Reference><Reference><Citation>Mody GM. Rheumatology in Africa-challenges and opportunities. Arthritis Res Ther 2017;19:49.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5341350</ArticleId><ArticleId IdType="pubmed">28270202</ArticleId></ArticleIdList></Reference><Reference><Citation>Genga EK, Moots RJ, Oyoo OG, Otieno FO.. Building a rheumatology team for East Africa: a call for action! Rheumatology 2017;56:1441&#x2013;2.</Citation><ArticleIdList><ArticleId IdType="pubmed">28031440</ArticleId></ArticleIdList></Reference><Reference><Citation>Strait A, Graf J, Margaretten M, Yazdany J, Goglin S.. Race, ethnicity, and disparities in rheumatology educational materials. Arthritis Care Res 2022;74:1416&#x2013;20.</Citation><ArticleIdList><ArticleId IdType="pubmed">33768717</ArticleId></ArticleIdList></Reference><Reference><Citation>
Fellowships - International Society of Nephrology: International Society of Nephrology; 2022. https://www.theisn.org/in-action/grants/fellowship/#special-fellow (1 November 2022, date last accessed).</Citation></Reference><Reference><Citation>Swanepoel CR, McCulloch MI, Abraham G. et al. Challenges for sustainable end-stage kidney disease care in low-middle-income countries: the problem of the workforce. Kidney Int Suppl 2020;10:e49&#x2013;54.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7031680</ArticleId><ArticleId IdType="pubmed">32149008</ArticleId></ArticleIdList></Reference><Reference><Citation>Schluger NW, Sherman CB, Binegdie A. et al. Creating a specialist physician workforce in low-resource settings: reflections and lessons learnt from the East African Training Initiative. BMJ Glob Health 2018;3:e001041.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6144898</ArticleId><ArticleId IdType="pubmed">30245867</ArticleId></ArticleIdList></Reference><Reference><Citation>Obaseki DO, Carter JE.. Training specialists in developing countries: a new model. J Pan African Thorac Soc 2020;2:4&#x2013;5.</Citation></Reference><Reference><Citation>
International League of Rheumatology Grant Projects: International League of Rheumatology. 2022. http://www.ilar.org/projects/ (1 November 2022, date last accessed).</Citation></Reference><Reference><Citation>von Elm E, Altman DG, Egger M. et al. The Strengthening the Reporting of Observational Studies in Epidemiology (STROBE) statement: guidelines for reporting observational studies. Lancet 2007;370:1453&#x2013;7.</Citation><ArticleIdList><ArticleId IdType="pubmed">18064739</ArticleId></ArticleIdList></Reference><Reference><Citation>Kroll M, Phalkey RK, Kraas F.. Challenges to the surveillance of non-communicable diseases&#x2013;a review of selected approaches. BMC Public Health 2015;15:1243.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4682212</ArticleId><ArticleId IdType="pubmed">26672992</ArticleId></ArticleIdList></Reference><Reference><Citation>Feldman CH, Speyer C, Ashby R. et al. Development of a set of lupus-specific, ambulatory care-sensitive, potentially preventable adverse conditions: a Delphi consensus study. Arthritis Care Res 2021;73:146&#x2013;57.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7165052</ArticleId><ArticleId IdType="pubmed">31628721</ArticleId></ArticleIdList></Reference></ReferenceList></PubmedData></PubmedArticle></PubmedArticleSet>